JNJ
JNJ
US4781601046
Johnson & Johnson
Loading chart...

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Latest News

Related stocks

ABBV
ABBV • United States
AbbVie Inc.
276.47 USD
488.55B USD 1Y +17.8%
MRK
MRK • United States
Merck & Company, Inc.
145.6 USD
359.22B USD 1Y +64.8%
LLY
LLY • United States
Eli Lilly and Company
1,179.27 USD
1.05T USD 1Y +38.3%
AMGN
AMGN • United States
Amgen Inc.
414.87 USD
224.29B USD 1Y +38.3%
GILD
GILD • United States
Gilead Sciences, Inc.
151.17 USD
187.44B USD 1Y +24.4%
PFE
PFE • United States
Pfizer, Inc.
28.28 USD
161.19B USD 1Y +8.3%
BMY
BMY • United States
Bristol-Myers Squibb Company
59.12 USD
120.77B USD 1Y +33.8%
BIIB
BIIB • United States
Biogen Inc.
225.71 USD
33.35B USD 1Y +44.7%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

5/7 Elevated
5Y Volatility
17.7% p.a.
Max Drawdown (5Y)
-23.6%
Sharpe Ratio (5Y)
0.41
Beta Factor
0.21
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
ende